Merck | Q2 2025: Stable results driven by oncology growth

Pharmaceutical giant Merck entered the second quarter of 2025 in somewhat mixed shape. Although the company unveiled new successes in oncology and added promising products to its portfolio through acquisitions, overall results were marred by a sharp decline in vaccine revenues, particularly Gardasil in China. Investors are thus watching with some caution whether this shortfall can be replaced by new opportunities and whether management's strategic moves will indeed ensure a return to longer-term growth.

At the same time,Merck $MRK has shown that it maintains strong profitability and the ability to invest billions of dollars in research and development despite short-term pressures. The acquisition of Verona Pharma and the launch of a major $3 billion per year cost optimization program signal management's focus on future growth pillars. For shareholders and patients alike, the company remains a key player that will set trends in the treatment of cancer, cardiopulmonary diseases and…